New therapies for diabetes: Beyond injectable insulin and oral antidiabetics;Nuevas terapias en diabetes: Más allá de la insulina inyectable y de los antidiabéticos orales

Revista da Associacao Medica Brasileira

Volumn 54, Issue 5, 2008, Pages 447-454

  Alfonso, John Edwin Feliciano ^a   Ariza, Iván Darío Sierra ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Diabetes mellitus type 1; Diabetes mellitus type 2; Dipeptidyl peptidase IV; Glucagon like peptide 1; Hypoglycemic agents; Insulin

Indexed keywords

AMYLIN; AMYLOID; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN;

DRUG POTENTIATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AMYLOID; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN;

EID: 56349100617     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302008000500020     Document Type: Review

References (64)

1. Guías ALAD 2006 de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2. Bogota: Asociación Latinoamericana de Diabetes; 2006.
2. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C- peptide responses. J Clin Endocrinol Metab. 1986;63:492-8.
3. Ahrén B. Dipeptidyl peptidase-4 inhibitors. Diabetes Care. 2007;30:1344-50.
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-705.
5. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, et al. Endogenous GLP-1 controls endocrine pancreatic secretion and antropyloro-duodenal motility in humans. Gut. 2006;55:243-51.
6. Perfetti R, Zhou J, Doyle M, Egan JM. Glucagon like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increase cell mass in the pancreas of old glucose intolerant rats. Endocrinology. 2000;141:4600-5.
7. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology. 2003;144:5149-58.
8. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et a.l Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.J Clin Endocrinol Metab. 2003;88:2719-25.
9. Turton MD, O'shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon peptide-1 in the central regulation of feeding. Nature. 1996;379:69-72
10. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on disprsed acini from guinea pig pancreas. J Biol Chem. 1992;267:7402-5.
11. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatine (exendin-4) on glicemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35.
12. De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-100.
13. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, KimDD, Fineman MS. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-91.
14. Zinman B, Hoogwerf BJ, Duran S, Milton DR, Giaconia G, Kim DD, et al. The effect of adding exenatide to thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146:477-85.
15. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a ramdorized trial. Ann Intern Med. 2005;143:559-69.
16. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice daily exenatide and biphasic insulin aspartat in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non inferiority study. Diabetologia. 2007;50:259-67.
17. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am Health Syst Pharm 2005; 62: 173-181
18. Keating GM. Exenatide. Drugs 2005; 65: 1681-1692
19. Amylin pharmaceuticals, Inc. Byetta T (exenatide injection: prescribing information) [cited 2007 ago 24]. Available from: http://www.byetta.com.
20. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effect of once-weekly dosing of a long-acing release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-93.
21. Deacon CF. Therapeutic strategies based upon glucagon-like peptide 1. Diabetes. 2004;53:2181-9.
22. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-10.
23. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide analog lirtaglutide (NN2211): a 12 week, double blind, randomized controlled trial. Diabetes Care. 2004;27:1335-42.
24. Feinglos MN, Saad MF, Pi Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 nalogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabetes Med 2005;22:1016-23.
25. FierceBiotech. Press release: liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising [cited 2007 aug 24]. Disponible en URL http://www.fiercebiotech.com/press-releases/press-release- liraglutide-improves-glucose-control-and-lowers-body-weight-two-phase-3. [Consultado 24 de agosto de 2007]
26. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and a meta-analisis. JAMA 2007; 298: 194-206
27. Johl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substancially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 424-429
28. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084
29. Mari A, Sallas WM, He L, Watson C, Ligueros-seylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor improves model-assessed beta cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894
30. Nauck MA, Mininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonlurea, glipizide, in patients with type 2 diabetes inadecuately controlled on metformina alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205
31. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987
32. Merck & Co, Inc. Januvia T (sitagliptin: prescribing information) [Internet]. Disponible en URL http://www.januvia.com [Consultado 28 de agosto de 2007]
33. Merck & Co, Inc. Janumet T (sitagliptin / metformin HCL: prescribing information) [Internet]. Disponible en URL http://www.janumet.com [Consultado 28 de agosto de 2007]
34. Rosenstock J, Baron MA, Camisasca RP, Ctressier F, Couturier A, Dejager S. Efficacy and tolerabilyty of initial combination therapy with vildagliptina and pioglitazone compared monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 175-185
35. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, doiuble-blind, randomized trial. Diabetes Care 2007: 30: 217-223
36. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over a year in drug naïve patients with type 2 diabetes. Diabetes Med 2007; doi:10.1111/j.1464-5491.2007.02191.x.
37. Schlesselman LS. Vildagliptin. Formulary 2006; 41: 494-500
38. Novartis Farmacéutica. Galvus® (Vildagliptina) Monografía del producto. México 2007
39. Mendivil CO, Sierra ID. Nuevos medicamentos antidiabéticos. En: Sierra ID, Mendivil CO, et al. Hacia el manejo práctico de la diabetes mellitus tipo 2. 3Ed. Editorial kimpres Ltda. 2006
40. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006; 29: 435-449
41. Kruger DF, Aronoff SL, Edelman SV. Through the Looking Glass: Current and Future Perspectives on the Role of Hormonal Interplay in Glucose Homeostasis. Diabetes Educ 2007; 33(Suppl2): 32S-46S.
42. Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Therapeutics 2005; 27: 1500-1512.
43. Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clin Diabetes. 2002;20: 137-144.
44. Lutz TA, MolletA, Rushing PA, et al. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord. 2001; 25:1005-1011.
45. Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, et al. Effect on pramlintide on saciety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48: 838-848
46. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 1992; 339:1179-1180.
47. Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type 2 diabetes. Diabetes 1991; 40:1615-1619.
48. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, et al. Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes. Diabetes Technol Ther 2002 ; 4:51-61.
49. Hollander PA, Levi P, Fineman MS, Maggs DG, Shen LZ, strobel SA, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003; 26 :784-790.
50. Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism. 2003; 52: 1638-1642.
51. Amylin pharmaceuticals, Inc. Symlin T (pramlintide acetate injection: prescribing information) [Internet]. Disponible en URL http://www.symlin.com [Consultado 3 de septiembre de 2007]
52. Singh-Franco D, Robles G, Gazze D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clin Therapeutics 2007; 29: 535-562
53. Mendivil CO, Sierra ID. Acción insulínica y Resistencia a la insulina: aspectos moleculares. Rev Fac Med Univ Nac Colomb 2005; 53: 843-853.
54. Hollander PA. Evolution of pulmonary insulin delivery system (Exubera) for patients with diabetes. MedGenMed 2007; 9: 45
55. Mendivil CO, Sierra ID. Insulinoterapia. En: Sierra ID, Mendivil CO, et al. Hacia el manejo práctico de la diabetes mellitus tipo 2. 3Ed. Editorial kimpres Ltda. 2006
56. Ceglia L, Lau J, Pittas AG. Meta-analysis: Efficacy and safety of inhalated insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145: 665-675
57. Royle P, Waugh N, McAuley L, McIntyre L, Thomas S. Inhaled insulin in diabetes mellitus. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD003890. DOI: 10.1002/14651858.CD003890.pub2.
58. Pfizer Inc. ExuberaT (insulin human [rDNA origin]) Inhalation Powder: prescribing information) [Internet]. Disponible en URL http://www.exubera.com [Consultado 7 de septiembre de 2007]
59. Pfizer Inc. ExuberaT (insulina humana inhalada: Ficha técnica) [Internet]. Disponible en URL http://www.pfizer.es/FichasTecnicas/ FTEXUBERA%203MG-MAR07-V04.pdf [Consultado 7 de septiembre de 2007]
60. Ghosh S, Collier S. Inhaled insulins. Postgrad Med J 2007; 83: 178-81
61. Becker RH, Sha S, Frick AD, Fountaine RJ. The effect of smoking cessation and subsequent resumption on absortion of inhaled insulin. Diabetes Care 2006; 29: 277-282
62. Pfizer Inc. ExuberaT [Internet]. Disponible en: http://www.exubera.com/ content/con_index.jsp?setShowOn=../content/con_index.jsp&setShowHighlightOn= ../content/con_index.jsp [Consultado 11 de Enero de 2008]
63. Isaji M. Sodium-glucose cotransporters inhibitors for diabetes. Curr Opin Investig Drugs 2007; 8: 285-292
64. Rayasam GV, Tulasi VK, Davis JA, Bansai VS. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin Ther 2007; 11: 661-671